Advertisement

Supportive Care in Cancer

, Volume 13, Issue 11, pp 870–877 | Cite as

Neoplastic fever: a neglected paraneoplastic syndrome

  • Jason A. Zell
  • Jae C. Chang
Review Article

Abstract

Neoplastic fever, a paraneoplastic syndrome caused by cancer itself, represents a diagnostic challenge for the clinician and is an important issue in supportive oncology. Timely recognition of this febrile condition by differentiating it from other cancer-associated fevers, such as infection and drug reaction, is essential for effective patient management. Although the pathophysiology of neoplastic fever is not well understood, it is suspected to be cytokine mediated. In clinical practice, when a patient with cancer presents with unexplained fever, extensive diagnostic studies are needed to differentiate neoplastic fever from nonneoplastic fever. Only after excluding identifiable etiologies of fever can the diagnosis of neoplastic fever be suspected. According to our experience, the naproxen test is a safe and useful test in differentiating neoplastic fever from infectious fever in patients with cancer. In addition, naproxen and other nonsteroidal anti-inflammatory drugs have been effective in the management of neoplastic fever and offer a significant palliative benefit for the patient.

Keywords

Neoplastic fever Fever palliation Fever of unknown origin Naproxen test Analgesics Antipyretics 

References

  1. 1.
    Anonymous (2002) Leukine (sargramostim). Package Insert Rev 0230-0233:1–2Google Scholar
  2. 2.
    Anonymous (2002) Neupogen (filgrastim). Physician Package Insert 1–29Google Scholar
  3. 3.
    Arnow PM, Flaherty JP (1997) Fever of unknown origin. Lancet 350:575–580PubMedGoogle Scholar
  4. 4.
    Ashford RF, McLachlan A, Nelson I, Mughal T, Pickering, D (1980) Pyrexia after cisplatin. Lancet 2:691–692PubMedGoogle Scholar
  5. 5.
    Beaupre DM, Talpaz M, Marini FC III, Cristiano RJ, Roth JA, Estrov Z, Albitar M, Freedman MH, Kurzrock R (1999) Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. Cancer Res 59:2971–2980PubMedGoogle Scholar
  6. 6.
    Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52:3317–3322PubMedGoogle Scholar
  7. 7.
    Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Negrier S, Philip T, Favrot M (1997) Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 72:424–430PubMedGoogle Scholar
  8. 8.
    Bodel P (1974) Generalized perturbations in host physiology caused by localized tumors. Tumors and fever. Ann N Y Acad Sci 230:6–13PubMedGoogle Scholar
  9. 9.
    Bodel P, Ralph P, Wenc K, Long JC (1980) Endogenous pyrogen production by Hodgkin’s disease and human histiocytic lymphoma cell lines in vitro. J Clin Invest 65:514–518PubMedGoogle Scholar
  10. 10.
    Bondy PK, Bodel P (1971) Mechanism of action of pyrogenic and antipyretic steroids in vitro. Ciba Found Symp 101–113Google Scholar
  11. 11.
    Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14:520–535PubMedGoogle Scholar
  12. 12.
    Browder AA, Huff JW, Petersdorf RG (1961) The significance of fever in neoplastic disease. Ann Intern Med 55:932–942PubMedGoogle Scholar
  13. 13.
    Carter JJ, McLaughlin ML, Bern MM (1983) Bleomycin-induced fatal hyperpyrexia. Am J Med 74:523–525PubMedGoogle Scholar
  14. 14.
    Cashman TM, Starns RJ, Johnson J, Oren J (1979) Comparative effects of naproxen and aspirin on fever in children. J Pediatr 95:626–629PubMedGoogle Scholar
  15. 15.
    Chang JC (1987) How to differentiate neoplastic fever from infectious fever in patients with cancer: usefulness of the naproxen test. Heart Lung 16:122–127PubMedGoogle Scholar
  16. 16.
    Chang JC (1988) Antipyretic effect of naproxen and corticosteroids on neoplastic fever. J Pain Symptom Manage 3:141–144PubMedGoogle Scholar
  17. 17.
    Chang JC (1989) Naproxen test in the differential diagnosis of fever of undetermined origin in patients with cancer. Cancer Ther Control 1:57–66Google Scholar
  18. 18.
    Chang JC (1989) Neoplastic fever. A proposal for diagnosis. Arch Intern Med 149:1728–1730PubMedGoogle Scholar
  19. 19.
    Chang JC, Appleby J, Bennett JM (1974) Nitroblue tetrazolium test in Hodgkin disease and other malignant lymphomas. Arch Intern Med 133:401–403PubMedGoogle Scholar
  20. 20.
    Chang JC, Gross HM (1984) Utility of naproxen in the differential diagnosis of fever of undetermined origin in patients with cancer. Am J Med 76:597–603PubMedGoogle Scholar
  21. 21.
    Chang JC, Gross HM (1985) Neoplastic fever responds to the treatment of an adequate dose of naproxen. J Clin Oncol 3:552–558PubMedGoogle Scholar
  22. 22.
    Chung KF, Snashall PD (1983) Suppression of prolonged fever during treatment of pulmonary tuberculosis: importance of using twice versus single daily dose of prednisolone. Postgrad Med J 59:373–375PubMedGoogle Scholar
  23. 23.
    Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325(3):164–170PubMedGoogle Scholar
  24. 24.
    Cunha BA (1996) Fever of unknown origin. Infect Dis Clin North Am 10:111–127PubMedGoogle Scholar
  25. 25.
    Dinarello CA, Wolff SM (1978) Pathogenesis of fever in man. N Engl J Med 298:607–612PubMedGoogle Scholar
  26. 26.
    Dinarello CA, Bunn PA (1997) Fever. Semin Oncol 24(3):288–298PubMedGoogle Scholar
  27. 27.
    Economos K, Lucci JA III, Richardson B, Yazigi R, Miller DS (1995) The effect of naproxen on fever in patients with advanced gynecologic malignancies. Gynecol Oncol 56:250–254PubMedGoogle Scholar
  28. 28.
    Fauci AS, Dale DC, Balow JE (1976) Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 84:304–315PubMedGoogle Scholar
  29. 29.
    Feigin RD, Shackelford PG, Choi SC, Flake KK, Franklin FA Jr, Eisenberg CS (1971) Nitroblue tetrazolium dye test as an aid in the differential diagnosis of febrile disorders. J Pediatr 78:230–237PubMedGoogle Scholar
  30. 30.
    Green HD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29–35PubMedGoogle Scholar
  31. 31.
    Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KVI, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedGoogle Scholar
  32. 32.
    Ishii E, Hara T, Mizuno Y, Ueda K (1988) Vincristine-induced fever in children with leukemia and lymphoma. Cancer 61:660–662PubMedGoogle Scholar
  33. 33.
    Jacoby GA, Swartz MN (1973) Fever of undetermined origin. N Engl J Med 289:1407–1410PubMedGoogle Scholar
  34. 34.
    Janssens AM, Offner FC, Van Hove WZ (2000) Bone marrow necrosis. Cancer 88:1769–1780PubMedGoogle Scholar
  35. 35.
    Johnson M (1996) Neoplastic fever. Palliat Med 10:217–224PubMedGoogle Scholar
  36. 36.
    Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021–2029PubMedGoogle Scholar
  37. 37.
    Kallio R, Bloigu A, Surcel HM, Syrjala H (2001) C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumours and lymphomas. Support Care Cancer 9:124–128PubMedGoogle Scholar
  38. 38.
    Kathula SK, Shah K, Polenakovik H, Koduri J (2003) Cyclo-oxygenase II inhibitors in the treatment of neoplastic fever. Support Care Cancer 11:258–259PubMedGoogle Scholar
  39. 39.
    Keinanen-Kiukaanniemi S, Simila S, Kouvalainen K (1980) Oral antipyretic therapy evaluation of the propionic acid derivatives ibuprofen, ketoprofen, fenoprofen and naproxen. Padiatr Padol 15:139–144PubMedGoogle Scholar
  40. 40.
    Klastersky J (1971) Effectiveness of adrenal corticosteroids in the management of severe bacterial infections. Rev Eur Etud Clin Biol 16:413–417PubMedGoogle Scholar
  41. 41.
    Knupp C, Pekala PH, Cornelius P (1988) Extensive bone marrow necrosis in patients with cancer and tumor necrosis factor activity in plasma. Am J Hematol 29(4):215–221PubMedGoogle Scholar
  42. 42.
    Kurzrock R (2001) The role of cytokines in cancer-related fatigue. Cancer 92:1684–1688PubMedGoogle Scholar
  43. 43.
    Lobell M, Boggs DR, Wintrobe MM (1966) The clinical significance of fever in Hodgkin’s disease. Arch Intern Med 117:335–342Google Scholar
  44. 44.
    Lusch CJ, Serpick AA, Slater L (1968) Antipyretic effect of indomethacin in patients with malignancy. Cancer 21:781–786PubMedGoogle Scholar
  45. 45.
    Pangalis GA, Dimopoulou MN, Angelopoulou MK, Tsekouras C, Vassilakopoulos TP, Vaiopoulos G, Siakantaris MP (2001) Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol 18:99–107PubMedGoogle Scholar
  46. 46.
    Park BH, Fikrig SM, Smithwick EM (1968) Infection and nitroblue-tetrazolium reduction by neutrophils. A diagnostic acid. Lancet 2:532–534PubMedGoogle Scholar
  47. 47.
    Petersdorf RG (1965) Fever and cancer. Hosp Med 1:2–5Google Scholar
  48. 48.
    Plaisance KI, Mackowiak PA (2000) Antipyretic therapy: physiologic rationale, diagnostic implications, and clinical consequences. Arch Intern Med 160:449–456PubMedGoogle Scholar
  49. 49.
    Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU (1986) Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 4:234–243PubMedGoogle Scholar
  50. 50.
    Rawlins MD, Luff RH, Cranston WI (1970) Pyrexia in renal carcinoma. Lancet 1:1371–1373PubMedGoogle Scholar
  51. 51.
    Schimpff SC (1986) Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 80:13–20Google Scholar
  52. 52.
    Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R (1995) Serum interleukin-6 levels correlate with prognosis in diffuse lareg cell lymphoma. J Clin Oncol 13:575–582PubMedGoogle Scholar
  53. 53.
    Shah KA, Greenwald E, Levin J, Rosen N, Zumoff B (1982) Streptozocin-induced eosinophilia and fever: a case report. Cancer Treat Rep 66:1449–1451Google Scholar
  54. 54.
    Smithson WA, Gronert GA, Moss KK (1983) Dantrolene and potentially fatal hyperthermia secondary to L-asparaginase. Cancer Treat Rep 67:318–319PubMedGoogle Scholar
  55. 55.
    Sokal JE, Shimaoka K (1967) Pyrogen in the urine of febrile patients with Hodgkin’s disease. Nature 215:1183–1185Google Scholar
  56. 56.
    Tsavaris N, Zinelis A, Karabelis A, Beldecos D, Bacojanis C, Milonacis N, Karvounis N, Kosmidis P (1990) A randomized trial of the effect of three non-steroid anti-inflammatory agents in ameliorating cancer-induced fever. J Intern Med 228:451–455PubMedGoogle Scholar
  57. 57.
    Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A(3):319–324PubMedGoogle Scholar
  58. 58.
    Vanderschueren S, Knockaert D, Adriaenssens T, Demey W, Durnez A, Blockmans D, Bobbaers H (2003) From prolonged febrile illness to fever of unknown origin: the challenge continues. Arch Intern Med 163:1033–1041PubMedGoogle Scholar
  59. 59.
    Vanderschueren S, Knockaert DC, Peetermans WE, Bobbaers HJ (2003) Lack of value of the naproxen test in the differential diagnosis of prolonged febrile illnesses. Am J Med 115:572–575PubMedGoogle Scholar
  60. 60.
    Vasser Stats (2004) Clinical calculator 1. From an observed sample: estimates of population prevalence, sensitivity, specificity, predictive values, and likelihood ratios. http://faculty.vassar.edu/lowry/clin1.htmlGoogle Scholar
  61. 61.
    Wolfe LS, Pappius HM, Marion J (1976) The biosynthesis of prostaglandins by brain tissue in vitro. Adv Prostaglandin Thromboxane Res 1:345–355PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.Divisions of Hematology/Oncology and Epidemiology, Chao Family Comprehensive Cancer CenterUniversity of California-Irvine Medical CenterOrangeUSA
  2. 2.Division of Hematology/Oncology, Chao Family Comprehensive Cancer CenterUniversity of California-Irvine Medical CenterOrangeUSA

Personalised recommendations